[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:open-angle-glaucoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":216,"states":217},"Open Angle Glaucoma",33,22,[8,16,23,30,36,42,48,54,60,66,72,79,85,91,98,104,110,116,122,128,134,140,146,153,160,167,173,179,185,191,198,204,210],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06066645","Travoprost Intraocular Implant + iStent Infinite",[12],"Phase 4","RECRUITING","2026-08-26T02:15:46.655893Z","2026-07-05T05:32:16.739308Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07075718","Phase 2\u002FPhase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",[20],"Phase 2\u002FPhase 3","2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.537910Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06267274","A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes",[27],"Phase 1","2026-08-26T02:18:34.622081Z","2026-05-05T02:43:29.395375Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06289491","A Trial of Hydrus Microstent Versus Goniotomy",[],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.366499Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07408154","Direct vs Standard SLT for Glaucoma: A Noninferiority Trial",[12],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.355638Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05624398","Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery",[],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.223275Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07325240","24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients",[12],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:28.867111Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06685211","Electrical Stimulation for Vision Neuroenhancement in Glaucoma",[],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.021890Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07209410","Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%\u002FLatanoprost 0.005% to Treat Glaucoma",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.798265Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07220876","Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma",[],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.635858Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":77,"content_modified":78},"NCT07495852","Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",[76],"Phase 3","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:27.288357Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07290244","Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)",[27],"2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.899219Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07217678","Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use",[12],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:28.673732Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT07354477","Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation",[95],"Phase 2","2026-08-26T02:16:10.529598Z","2026-05-05T02:43:26.684329Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone",[12],"2026-08-26T02:18:24.494016Z","2026-05-05T02:35:31.930255Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg",[],"2026-08-26T02:17:07.954622Z","2026-05-13T02:55:06.699642Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07281391","IOP Reduction in Pigmentary Glaucoma Using DSLT",[],"2026-08-26T02:18:03.638950Z","2026-05-13T02:55:06.684307Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06953349","Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis",[],"2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.593794Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05685485","Tied Tube Trial in Glaucoma Surgery",[],"2026-08-26T02:19:13.549512Z","2026-05-13T02:55:06.371046Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06883123","Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost",[12],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.367431Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07465913","Rocklatan vs Latanoprost Post-DSLT",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.965155Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07228221","Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma",[12],"2026-08-26T02:15:54.846520Z","2026-05-05T02:35:31.756532Z",{"nct_id":147,"title":148,"phases":149,"status":150,"updated_at":151,"content_modified":152},"NCT06809647","A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma",[],"NOT_YET_RECRUITING","2026-08-26T02:18:17.950264Z","2026-05-05T02:43:27.760526Z",{"nct_id":154,"title":155,"phases":156,"status":150,"updated_at":158,"content_modified":159},"NCT07619482","Topical Insulin for Glaucoma (TING2)",[157],"Phase 1\u002FPhase 2","2026-08-26T02:18:01.700186Z","2026-06-04T01:30:07.904073Z",{"nct_id":161,"title":162,"phases":163,"status":164,"updated_at":165,"content_modified":166},"NCT07520175","A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:40.612983Z","2026-06-16T05:54:07.886207Z",{"nct_id":168,"title":169,"phases":170,"status":164,"updated_at":171,"content_modified":172},"NCT07480343","5-Year Postoperative Outcomes of Patients Who Completed the CREST Study",[],"2026-08-26T02:15:40.343619Z","2026-06-16T05:54:07.885085Z",{"nct_id":174,"title":175,"phases":176,"status":164,"updated_at":177,"content_modified":178},"NCT07073937","Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty",[],"2026-08-26T02:17:51.502023Z","2026-06-16T05:54:07.852827Z",{"nct_id":180,"title":181,"phases":182,"status":164,"updated_at":183,"content_modified":184},"NCT06925477","Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT",[],"2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.841268Z",{"nct_id":186,"title":187,"phases":188,"status":164,"updated_at":189,"content_modified":190},"NCT00338065","External Influences Upon Ocular Homeostasis",[],"2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.943415Z",{"nct_id":192,"title":193,"phases":194,"status":195,"updated_at":196,"content_modified":197},"NCT06964191","Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension",[95],"ACTIVE_NOT_RECRUITING","2026-08-03T03:06:52.862370Z","2026-05-05T02:43:28.842676Z",{"nct_id":199,"title":200,"phases":201,"status":195,"updated_at":202,"content_modified":203},"NCT04499248","AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension",[157],"2026-08-03T01:57:36.164517Z","2026-05-05T02:43:27.445834Z",{"nct_id":205,"title":206,"phases":207,"status":195,"updated_at":208,"content_modified":209},"NCT06240312","Optic Nerve Head Strain as Biomarker for Glaucoma",[],"2026-08-03T03:28:38.624558Z","2026-05-05T02:43:28.558865Z",{"nct_id":211,"title":212,"phases":213,"status":195,"updated_at":214,"content_modified":215},"NCT05506423","Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes",[],"2026-08-03T02:10:37.231905Z","2026-06-16T05:54:08.033684Z",[],[218,222,226,230,234,237,240,243,246,250,253,256,259,262,265],{"state":219,"count":220,"slug":221},"California",11,"california",{"state":223,"count":224,"slug":225},"Texas",8,"texas",{"state":227,"count":228,"slug":229},"Pennsylvania",6,"pennsylvania",{"state":231,"count":232,"slug":233},"Florida",4,"florida",{"state":235,"count":232,"slug":236},"Georgia","georgia",{"state":238,"count":232,"slug":239},"South Carolina","south-carolina",{"state":241,"count":232,"slug":242},"Tennessee","tennessee",{"state":244,"count":232,"slug":245},"Utah","utah",{"state":247,"count":248,"slug":249},"Arizona",3,"arizona",{"state":251,"count":248,"slug":252},"Maryland","maryland",{"state":254,"count":248,"slug":255},"Massachusetts","massachusetts",{"state":257,"count":248,"slug":258},"Missouri","missouri",{"state":260,"count":248,"slug":261},"Nevada","nevada",{"state":263,"count":248,"slug":264},"Oklahoma","oklahoma",{"state":266,"count":248,"slug":267},"Wisconsin","wisconsin"]